|
Dr. Richard Ulevitch received his doctorate in biochemistry from the University of Pennsylvania in 1971. He joined The Scripps Research Institute (TSRI) in 1972 and is currently professor and chairman of the Department of Immunology at TSRI. The research in his laboratory has been focused on defining molecular mechanisms involved in innate immunity. This first started with studies using bacterial products, such as bacterial lipopolysaccharide (endotoxin, LPS). Initial work highlighted a key role for serum lipoproteins in binding of LPS. Subsequently, work from the Ulevitch laboratory resulted in the discovery of LPS binding protein (LBP) and the identification of CD14 as a key component in the recognition of LPS and other bacterial products. These studies resulted in clinical trials in man evaluating the role of a monoclonal antibody (MAb) to human CD14 in sepsis. Subsequent to these studies, the laboratory turned to defining the signaling pathways that initiate cell activation. Dr. Ulevitch has received numerous awards, has served on many advisory panels, and is a consultant for pharmaceutical and biotechnology companies.
| 